Invivyd (IVVD) Non-Current Assets (2021 - 2026)
Invivyd's (IVVD) quarterly Non-Current Assets came in at $36.8 million in Q2 2026, up 23.16% on a YoY basis from $29.9 million in Q2 2025, and up 25.0% quarter-over-quarter from $29.4 million in Q4 2025.
Analysis
Invivyd (IVVD) Non-Current Assets (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Non-Current Assets for 6 consecutive years, with $36.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Assets rose 23.16% year-over-year to $36.8 million; the trailing twelve-month figure through Jun 2026 stood at $125.4 million (up 28.74% YoY), and the FY2025 full-year result was $29.4 million, up 2.02% from the prior year.
- Non-Current Assets advanced to $36.8 million in Q2 2026 per IVVD's latest filing, from $29.4 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $36.8 million in Q2 2026 and bottomed at $2.0 million in Q1 2022.
- Historically, Non-Current Assets has averaged $14.0 million across 5 years, with a median of $5.9 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets sank 48.47% in 2022, then surged 588.74% in 2025.
- Over 5 years, Non-Current Assets stood at $6.2 million in 2022, then tumbled by 31.2% to $4.3 million in 2023, then soared by 570.56% to $28.8 million in 2024, then grew by 2.02% to $29.4 million in 2025, then gained by 25.0% to $36.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $36.8 million, $29.4 million, and $29.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 36.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.77 Mn |
| Dec 31, 2025 | 29.42 Mn |
| Sep 30, 2025 | 29.39 Mn |
| Jun 30, 2025 | 29.86 Mn |
| Mar 31, 2025 | 27.92 Mn |
| Dec 31, 2024 | 28.83 Mn |
| Sep 30, 2024 | 10.82 Mn |
| Jun 30, 2024 | 4.34 Mn |
| Mar 31, 2024 | 5.59 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 4.81 Mn |
| Jun 30, 2023 | 5.43 Mn |
| Mar 31, 2023 | 5.94 Mn |
| Dec 31, 2022 | 6.25 Mn |
| Sep 30, 2022 | 3.15 Mn |
| Jun 30, 2022 | 3.25 Mn |
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 3.38 Mn |
| Sep 30, 2021 | 6.12 Mn |
| Jun 30, 2021 | 1.93 Mn |